Archive \ Volume.13 2022 Issue 3

Differential Leucocytes Count: An Independent Predictor of Clinical Outcomes in SARS-CoV-2 Patients

Rofida Galal Eldein Mohamed , Elharam Ibrahim Abdallah , Abdel Rahim Mahmoud Muddathir , Ghfren S. Aloraini , Alaa Eltayeb Omer , Altaf Ali Mangi , Lienda Bashier Eltayeb

SARS-CoV-2 is a systemic infection that has a significant impact on the hemostasis and hematopoietic system. Lymphopenia may be considered a cardinal laboratory finding, with prognostic potential. The study aimed to determine the differential leukocyte count in SARS-CoV-2 among Sudanese patients, during the period from March to December 2020. A total of 787 subjects were enrolled 487 patients with COVID-19 and 300 healthy volunteers as a control group; their ages ranged from 29 to 89 years. 3 ml of EDTA venous blood samples were collected from each participant standard for CBC investigation and then analyzed by SPSS version 21 (Mean and Standard deviation). A significant association between leukocyte count among ICU, ER group, and control with (P. value 0.000), in addition, a significant association was revealed among mild group and control group in differential neutrophil count, differential lymphocyte count, and absolute neutrophil count (p. value 0.000), however non-significant in TWBC absolute mixed cell count, absolute lymphocyte count, and differential mixed cells count (value 0.7,0.2, 0.19) respectively. The study concluded that leukocytosis with neutrophilia and lymphopenia is associated with the severity of SARS-CoV-2 infection, and should be implicated as predict for a serious course of the disease as well as mortality.

How to cite:
Mohamed RGE, Abdallah EI, Muddathir ARM, Aloraini GS, Omer AE, Mangi AA, et al. Differential Leucocytes Count: An Independent Predictor of Clinical Outcomes in SARS-CoV-2 Patients. Arch. Pharm. Pract. 2022;13(3):11-5.
Mohamed, R. G. E., Abdallah, E. I., Muddathir, A. R. M., Aloraini, G. S., Omer, A. E., Mangi, A. A., & Eltayeb, L. B. (2022). Differential Leucocytes Count: An Independent Predictor of Clinical Outcomes in SARS-CoV-2 Patients. Archives Of Pharmacy Practice, 13(3),11-15.

Download Citation

1.        19). Radiol Bras. 2020;53:V-I. doi:10.1590/0100-3984.2020.53.2e1

2.        Welman A, Outhoff K. Evidence of the Clinical Efficacy of Antiviral Agents against SARS-CoV-2. Int J Pharma Res Allied Sci. 2021;10(3):94-111. doi:10.51847/E3AXGWu0IP

3.        Zhu Y, Li J, Pang Z. Recent insights for the emerging COVID-19: Drug discovery, therapeutic options and vaccine development. Asian J Pharm Sci. 2021;16(1):4-23. doi:10.1016/j.ajps.2020.06.001  

4.        Anis S, Khan MM, Ali Z, Khan A, Arsalan HM, Naeem S, et al. Novel corona virus disease (COVID-19): An updated review on epidemiology, pathogenicity, clinical course, treatments, migrant health concerns and risk factors predictions. Pak J Pharm Sci. 2021;34(5):1807-22.

5.        Zhang Y, Garner R, Salehi S, La Rocca M, Duncan D. Association between ABO blood types and coronavirus disease 2019 (COVID-19), genetic associations, and underlying molecular mechanisms: a literature review of 23 studies. Ann Hematol. 2021;100(5):1123-32. doi:10.1007/s00277-021-04489-w

6.        Baldassi F, Cenciarelli O, Malizia A, Gaudio P. Testing the identification effectiveness of an unknown outbreak of the Infectious Diseases Seeker (IDS) using and comparing the novel coronavirus disease (COVID-19) outbreak with the past SARS and MERS epidemics. J Infect Public Health. 2021;14(1):123-30. doi:10.1016/j.jiph.2020.11.014

7.        Peeri NC, Shrestha N, Rahman MS, Zaki R, Tan Z, Bibi S, et al. The SARS, MERS and novel coronavirus (COVID-19) epidemics, the newest and biggest global health threats: what lessons have we learned?. Int J Epidemiol. 2020;49(3):717-26. doi:10.1093/ije/dyaa033

8.        Chang YH, Yang SH, Wang TF, Lin TY, Yang KL, Chen SH. Complete blood count reference values of cord blood in Taiwan and the influence of gender and delivery route on them. Pediatr Neonatol. 2011;52(3):155-60. doi:10.1016/j.pedneo.2011.03.007

9.        Lippi G, Plebani M. Procalcitonin in patients with severe coronavirus disease 2019 (COVID-19): a meta-analysis. Clin Chim Acta. 2020;505:190-91. doi:10.1016/j.cca.2020.03.004

10.      Djakpo DK, Wang Z, Zhang R, Chen X, Chen P, Antoine MM. Blood routine test in mild and common 2019 coronavirus (COVID-19) patients. Biosci Rep. 2020;40(8):BSR20200817. doi:10.1042/BSR20200817

11.      Yun H, Sun Z, Wu J, Tang A, Hu M, Xiang Z. Laboratory data analysis of novel coronavirus (COVID-19) screening in 2510 patients. Clin Chim Acta. 2020;507:94-7. doi:10.1016/j.cca.2020.04.018

12.      Anurag A, Jha PK, Kumar A. Differential white blood cell count in the COVID-19: A cross-sectional study of 148 patients. Diabetes Metab Syndr. 2020;14(6):2099-102. doi:10.1016/j.dsx.2020.10.029

13.      Meo SA, Alhowikan AM, Al-Khlaiwi T, Meo IM, Halepoto DM, Iqbal M, et al. Novel coronavirus 2019-nCoV: prevalence, biological and clinical characteristics comparison with SARS-CoV and MERS-CoV. Eur Rev Med Pharmacol Sci. 2020;24(4):2012-9. doi:10.26355/eurrev20200220379

14.      Zhang JJ, Dong X, Cao YY, Yuan YD, Yang YB, Yan YQ, et al. Clinical characteristics of 140 patients infected with SARS‐CoV‐2 in Wuhan, China. Allergy. 2020;75(7):1730-41. doi:10.1111/all.14238

15.      Gao Y, Li T, Han M, Li X, Wu D, Xu Y, et al. Diagnostic utility of clinical laboratory data determinations for patients with the severe COVID‐19. J Med Virol. 2020;92(7):791-6. doi:10.1002/jmv.25770

16.      Guan WJ, Ni ZY, Hu Y, Liang WH, Ou CQ, He JX, et al. Clinical characteristics of coronavirus disease 2019 in China. N Engl J Med. 2020;382(18):1708-20. doi:10.1056/NEJMoa2002032

17.      Huang C, Wang Y, Li X, Ren L, Zhao J, Hu Y, et al. Clinical features of patients infected with 2019 novel coronavirus in Wuhan, China. Lancet. 2020;395(10223):497-506. doi:10.1016/S0140-6736(20)30183-5.

18.      Palladino M. Complete blood count alterations in COVID-19 patients: A narrative review. Biochem Med. 2021;31(3):030501. doi:10.11613/BM.2021.030501

19.      Moradi EV, Teimouri A, Rezaee R, Morovatdar N, Foroughian M, Layegh P, et al. Increased age, neutrophil-to-lymphocyte ratio (NLR) and white blood cells count are associated with higher COVID-19 mortality. Am J Emerg Med. 2021;40:11-4. doi:10.1016/j.ajem.2020.12.003

20.      Song H, Kim HJ, Park KN, Kim SH, Oh SH, Youn CS. Neutrophil to lymphocyte ratio is associated with in-hospital mortality in older adults admitted to the emergency department. Am J Emerg Med. 2021;40:133-7. doi:10.1016/j.ajem.2020.01.044

21.      Lagunas‐Rangel FA. Neutrophil‐to‐lymphocyte ratio and lymphocyte‐to‐C‐reactive protein ratio in patients with severe coronavirus disease 2019 (COVID‐19): a meta‐analysis. J Med Virol. 2020;92(10):1733-4. doi:10.1002/jmv.25819

22.      Yang AP, Liu JP, Tao WQ, Li HM. The diagnostic and predictive role of NLR, d-NLR and PLR in COVID-19 patients. In Immunopharmacol. 2020;84:106504. doi:10.1016/j.intimp.2020.106504

23.      Wang D, Hu B, Hu C, Zhu F, Liu X, Zhang J, et al. Clinical characteristics of 138 hospitalized patients with 2019 novel coronavirus-infected pneumonia in Wuhan, China. JaMa. 2020;323(11):1061-9. doi:10.1001/jama.2020.1585.